3rd Digital Exosome Based Therapeutic Development Summit

Memo

As the clinical development landscape grows and investment continues to pour into the industry, the field of exosome-based therapeutics is growing and maturing rapidly and excitingly. The 3rd Exosome-Based Therapeutic Development Summit returns with a more comprehensive agenda than ever before, reuniting leading pharma, biotech, technology providers and academic teams to advance therapeutically relevant exosome-based therapeutics in regenerative medicine, autoimmunity, COVID-19 and beyond. Deep diving into the key challenges such as sourcing, characterization, cargo loading, manufacturing and clinical development, this year’s summit will be your comprehensive roadmap to realizing, strategizing and advancing the full therapeutics and drug delivery opportunities offered by exosomes. Tailor-made to showcase the latest innovations and interactively discuss the industry's most important talking points, join leading biopharmaceutical Directors, VPs and C-Level Executives to successfully optimize, accelerate and scale your exosome-based therapeutics as next generation drugs for unmet clinical needs. Date and Time: On Tuesday November 16, 2021 at 9:30 am (ends Thursday November 18, 2021 at 5:00 pm) Prices: Drug Developer - Conference + Focus Day: USD 3296.00,Drug Developer - Conference Only: USD 2099.00,Academic and Research Institute Pricing - Conference + Focus Day: USD 2796.00,Academic and Research Institute Pricing - Conference Only: USD 1899.00,Standard Pricing - Conference + Focus Day: USD 4196.00,Standard Pricing - Conference Only: USD 2599.00 URLs: Tickets: https://go.evvnt.com/856682-2?pid=5569 Brochure: https://go.evvnt.com/856682-3?pid=5569 Speakers: Swetha Srinivasan, Senior Scientist, Abbvie, Jieun Lee, Scientist AgeX, Therapeutics, Shelley Hartman, CEO and Co-Founder, Aegle Therapeutics, Steve Stice, Senior PostDoc Fellow, Aruna Bio and University of Georgia, Andreia Silva, Senior PostDoc Fellow, AstraZeneca, David Greening, Associate Professor, Baker Heart and Diabetes Institute, Ian McNiece, CSO, Biocardia, James Thornton, Senior Director, Business Development, Codiak Biosciences, Joana Simoes Correia, CSO, Exogenus Therapeutics, Chris Baldwin, Deputy CEO, Exopharm, Mark Bodmer, President of R&D and CSO, Evelo Biosciences, Gianluca Roma, CEO, EV Therapeutics, Nam-Trung Nguyen, Professor, Griffith University, Chulhee Choi, CEO, ILIAS Biologics, Ishai Padawer, Director of Process Sciences, Mantra Bio, Lior Shaltiel, CEO, NurExone Biologic, Gerry McCauley, CEO, OmniSpirant, Mari Mitrani, CSO, Organicell Regenerative Medicine, Christopher Paradise, Vice President, Product Development and Innovation, Rion, Maureen Merrifield, SVP Regulatory Affairs, Rion, Dongsheng Cai, Professor Albert Einstein College of Medicine Collaborator and Advisor, StemXO, Shiran Shapira, Head of Research Laboratory, Health Promotion Center and Integrated Cancer Prevention Center, Sotirios Tsiodras, Professor of Medicine and Infectious Diseases, National and Kapodistrian University of Athens Medical School, Pieter Vader, Associate Professor, University Medical Center Utrecht, Mei He, Assistant Professor, University of Florida, Gerald W Dryden, Professor of Medicine, University of Louisville, Konstantin Glebov, Assistant Professor, Clinical Neuroscience, School of Medicine, University of Plymouth, David Haylock, CEO, VivaZome Therapeutics, Joe Nabhan, CSO, Vesigen